Journal of pancreatic cancer最新文献

{"title":"A Phase I/II Open-Label Multicenter Single-Arm Study of FABLOx (Metronomic 5-Fluorouracil Plus <i>nab</i>-Paclitaxel, Bevacizumab, Leucovorin, and Oxaliplatin) in Patients with Metastatic Pancreatic Cancer.","authors":"Vaibhav Sahai,&nbsp;M Wasif Saif,&nbsp;Aparna Kalyan,&nbsp;Philip A Philip,&nbsp;Caio M Rocha-Lima,&nbsp;Allyson Ocean,&nbsp;Michael S Ondovik,&nbsp;Diane M Simeone,&nbsp;Sibabrata Banerjee,&nbsp;Rafia Bhore,&nbsp;Chrystal U Louis,&nbsp;Vincent Picozzi","doi":"10.1089/pancan.2019.0012","DOIUrl":"https://doi.org/10.1089/pancan.2019.0012","url":null,"abstract":"<p><p><b>Purpose:</b> To evaluate safety and preliminary efficacy of metronomic 5-fluorouracil plus <i>nab</i>-paclitaxel, bevacizumab, leucovorin, and oxaliplatin (FABLOx) in patients with newly diagnosed metastatic pancreatic cancer (MPC). <b>Methods:</b> A total of 12 treatment-naive patients (aged 18-65 years, Eastern Cooperative Oncology Group performance status [ECOG PS] ≤1) with MPC received 5-fluorouracil 180 mg/m² per day (days 1-14 continuous infusion); <i>nab</i>-paclitaxel 75 mg/m², leucovorin 20 mg/m², and oxaliplatin 40 mg/m² (days 1, 8, and 15); and bevacizumab 5 mg/kg (days 1 and 15) administered intravenously in each 28-day cycle. The primary end-point was incidence of dose-limiting toxicities (DLTs) in cycle 1. Safety was further evaluated as a secondary end-point; preliminary efficacy was also examined. <b>Results:</b> Two DLTs (grade 3 anemia requiring transfusion and grade 3 mucositis unresponsive to treatment within 4 days of onset) were observed in one of six patients enrolled in dose cohort 1. Cohort 1 was expanded from 6 to 12 patients to further evaluate safety, per the investigators' recommendation. All patients discontinued treatment. The most common grade ≥3 adverse events were abdominal pain, fatigue, mucositis, and decreased neutrophil count. Objective response rate was 33% (four partial responses). Median progression-free survival (PFS) and overall survival (OS) were 5.6 (95% confidence interval [CI], 1.7-11.3) and 9.9 (95% CI, 4.4-13.2) months, respectively; 1-year PFS and OS rates were 12.2% (95% CI, 0.7-40.8) and 38.9% (95% CI, 12.6-65.0). <b>Conclusion:</b> FABLOx is feasible and tolerable in patients newly diagnosed with MPC. However, preliminary efficacy data are inconclusive for continued investigation in a phase II trial.</p>","PeriodicalId":94337,"journal":{"name":"Journal of pancreatic cancer","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1089/pancan.2019.0012","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41224873","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}